Center for Outcomes Research and Evaluation, Carolinas HealthCare System, Charlotte, North Carolina (Dr Mahabaleshwarkar, Ms Templin, Mr Gohs, Ms Mulder).
Department of Family Practice, Carolinas HealthCare System, Charlotte, North Carolina (Dr DeSantis).
Diabetes Educ. 2017 Oct;43(5):495-505. doi: 10.1177/0145721717726508. Epub 2017 Aug 22.
Purpose The purpose of the study was to examine the association between timely treatment intensification (TTI) and glycemic goal achievement in patients with type 2 diabetes (T2D) failing metformin monotherapy (MM). Methods This study was set at a large integrated health care system in the United States. The study cohort included T2D patients aged 18 to 85 years who were on MM between January 2009 and September 2013 and had an uncontrolled glycated hemoglobin (A1C) reading (≥8%) after at least 3 months of MM (corresponding date was index date). Secondary analyses were performed using A1C <7% as T2D control. TTI was defined as receipt of an add-on therapy within 180 days after the index date. Impact of TTI on glycemic goal achievement was determined using multivariate Cox proportional hazards regression. Patients were censored at their last A1C reading or health care visit during 2 years after the index date. Results The study cohort consisted of 996 patients, ~58% male and ~59% Caucasian, with a mean age of ~54 (±12) years. TTI was observed in 50.2% of the patients. The rate of glycemic goal achievement was higher in patients with TTI compared with patients without TTI (hazards ratio = 1.632, 95% confidence interval = 1.328-2.006). The results for the secondary analyses were largely consistent with the primary findings. Conclusions TTI positively affected glycemic goal achievement among T2D patients failing MM and could be a useful strategy to increase the currently low proportion of patients with their T2D controlled in the United States.
目的 本研究旨在探讨在二甲双胍单药治疗失败的 2 型糖尿病(T2D)患者中,及时治疗强化(TTI)与血糖目标达标之间的关系。
方法 本研究在美国一家大型综合性医疗保健系统中进行。研究队列包括年龄在 18 至 85 岁之间的 T2D 患者,他们在 2009 年 1 月至 2013 年 9 月期间接受二甲双胍单药治疗,并且在至少 3 个月的二甲双胍治疗后糖化血红蛋白(A1C)读数(≥8%)未得到控制(对应日期为索引日期)。使用 A1C<7%作为 T2D 对照组进行了二次分析。TTI 定义为在索引日期后 180 天内接受附加治疗。使用多变量 Cox 比例风险回归确定 TTI 对血糖目标达标率的影响。患者在索引日期后 2 年内最后一次 A1C 读数或就诊时被删失。
结果 研究队列包括 996 名患者,约 58%为男性,约 59%为白种人,平均年龄约为 54(±12)岁。50.2%的患者接受了 TTI。与未接受 TTI 的患者相比,接受 TTI 的患者血糖目标达标率更高(风险比=1.632,95%置信区间=1.328-2.006)。二次分析的结果与主要发现基本一致。
结论 TTI 对二甲双胍单药治疗失败的 T2D 患者的血糖目标达标率有积极影响,可能是提高美国目前控制不佳的 T2D 患者比例的一种有效策略。